TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03769714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution for Injection
Description: Injection of 20mL of 0.9%Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
Study: NCT01238380

Intervention type: OTHER
Intervention: patient care pathway
Description: Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 \& IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change.
Study: NCT01401556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifaceted quality improvement intervention
Study: NCT03532100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 0:1 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 0:1 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 1:6 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
Study: NCT03197987

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cap
Description: Cap-assisted colonoscopy
Study: NCT02130830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 2,5% lidocaine + 2,5% prilocaine gel
Description: The topical gel is administered in the anal canal at the moment of the anoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
Study: NCT03326765

Intervention type: PROCEDURE
Group type: OTHER
Intervention: polysomnography
Description: type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
Study: NCT04420884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazostinag
Description: Dazostinag intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazostinag
Description: Dazostinag intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazostinag
Description: Dazostinag intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazostinag
Description: Dazostinag intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazostinag
Description: Dazostinag intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazostinag
Description: Dazostinag intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazostinag
Description: Dazostinag intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazostinag
Description: Dazostinag intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Carboplatin or Cisplatin intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil intravenous infusion
Study: NCT03326765

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Actigraphy
Description: type of sleep study based on bracelet around the wrist

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Actigraphy
Description: type of sleep study based on bracelet around the wrist
Study: NCT04059484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: Pharmaceutical form: Capsule~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Pharmaceutical form: Solution for injection~Route of administration: Intramuscular

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Pharmaceutical form:Tablets or capsules~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Pharmaceutical form: Tablets or capsules~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Pharmaceutical form: Tablets or capsules~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Pharmaceutical form: Tablets or capsules~Route of administration: Oral
Study: NCT03532100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 1:6 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 1:6 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
Study: NCT02241655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a pragmatic EEG-guided anesthetic protocol
Study: NCT02668770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
Study: NCT02120300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00657293

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm training program
Description: Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Purdue pegboard test (sham)
Description: In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
Study: NCT03639623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar
Description: Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
Study: NCT01830283

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: varicella vaccine
Description: The providers would get varicella vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: varicella vaccine
Description: The providers would get varicella vaccine
Study: NCT03754127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham transcranial direct current stimulation
Study: NCT03709277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-Driven Intervention
Description: The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
Study: NCT01329276

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Symbicort® forte Turbohaler®
Description: 320 µg budesonide / 9 µg formoterol fumarate dihydrate

Intervention type: DRUG
Group type: OTHER
Intervention: Symbicort® forte Turbohaler®
Description: 320 µg budesonide / 9 µg formoterol fumarate dihydrate
Study: NCT00054327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo total body irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo total body irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo total body irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo total body irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo total body irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transfusion
Study: NCT01956097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HX106 590mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HX106 1180mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02745678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thermosensitive gel rectal formulation
Study: NCT02231892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: HAC coil (real rTMS or sham rTMS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: HAC coil (real rTMS or sham rTMS)
Study: NCT02024360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: 16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
Study: NCT02117960

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: 4 cap 1 g Omega-3 per day for 2 months
Study: NCT00656266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo medication
Description: medication that looks like mycophenolate mofetil
Study: NCT02117960

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 cap 1 g Placebo(paraffin) per day for 2 months
Study: NCT02180724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (ACP-196)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (ACP-196)
Study: NCT01897350

Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging
Study: NCT01748708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy
Description: 100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
Study: NCT02475343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Schiotz tonometer
Description: The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Schiotz tonometer
Description: The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
Study: NCT01191736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No training, assessed within 60 mins
Description: Subjects receive no training in resuscitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultra-brief video; assessed in 60 mins
Description: Subjects receive an ultra-brief (90-second) video on hands-only CPR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video; assessed in 60 mins
Description: Subjects receive a brief (5-minute) video on hands-only CPR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video + hands-on; ass'd in 60 mins
Description: Subjects receive a brief (5-minute) video with hands-on manikin practice
Study: NCT02951130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: The study intervention is an intravenous infusion of milrinone or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (5% Dextrose)
Description: The study intervention is an intravenous infusion of milrinone or placebo
Study: NCT03477968

Intervention type: DIAGNOSTIC_TEST
Intervention: DDimer test
Description: Measuring the level of DDimer in blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: DDimer test
Description: Measuring the level of DDimer in blood sample
Study: NCT01191736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultra-brief video; assessed at 2 months
Description: Subjects see ultra-brief video (90-seconds), are assessed two months later

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video; assessed 2 months later
Description: Subjects see brief video (5 minutes), are then assessed two months later

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video + hands-on; ass'd 2 ms later
Description: Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
Study: NCT01979666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitrate patch
Description: patients in the study group will get a nitrate patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: control group patients will get a placebo patch

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI scan
Description: MRI scan after 6 weeks of treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan after 6 weeks of treatment
Study: NCT04104191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-1000AF System
Description: The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
Study: NCT03402204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Description: Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Description: Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease.
Study: NCT04251897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel support surface
Description: This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel support surface
Description: This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
Study: NCT06552949

Intervention type: PROCEDURE
Intervention: Emergent laparoscopic cholecystectomy guided by ICG cholangiography (ELC-ICGC)
Description: Emergent conventional laparoscopic cholecystectomy